Navigation Links
Potential cholesterol lowering drug has breast cancer fighting capabilities
Date:6/17/2014

COLUMBIA, Mo. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

"Cholesterol is a molecule found in all animal cells and serves as a structural component of cell membranes," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at MU. "Because tumor cells grow rapidly they need to synthesize more cholesterol. Scientists working to cure breast cancer often seek out alternative targets that might slow or stop the progression of the disease, including the elimination of the cancerous cells. In our study, we targeted the production of cholesterol in cancer cells leading to death of breast cancer cells."

Previous studies suggest that 70 percent of breast cancers found in women are hormone dependent and can be treated with anti-hormone medicines such as tamoxifen. Although tumor cells may initially respond to therapies, most eventually develop resistance which causes breast cancer cells to grow and spread. Cholesterol also can contribute to the development of anti-hormone resistance because cholesterol is converted into hormones in tumor cells. Therefore, these cholesterol-forming pathways are attractive therapeutic targets for the treatment of breast cancer.

Using compounds initially developed by Roche Pharmaceuticals for the treatment of high cholesterol, which reduces cholesterol in a different manner than the widely used statins, Hyder and his team administered the molecule to human breast cancer cells. They found that the compound was effective in reducing human breast cancer cell growth and often caused cancer cell death. Most interestingly they found that the cholesterol lowering drug they tested destroyed an estrogen receptor, a protein which encourages the tumor cells to grow.

Equipped with this information, Hyder and the team tested the results in mice with breast cancer. Following injection of the compound, Hyder found that the molecule was effective at killing breast cancer cells by reducing the presence of estrogen receptors in tumor cells, Hyder said.

"The compound exhibited anti-tumor properties in both human samples, which were outside the body, and in samples that were administered by injection into the mice," Hyder said. "In both cases, the proteins that cause tumors to grow were eliminated, leading to more aggressive cell death."

Hyder believes that further clinical testing can lead to a drug that has the dual purpose of fighting high cholesterol and cancer.


'/>"/>

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia
Source:Eurekalert  

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential cholesterol lowering drug has breast cancer fighting capabilities
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... DuPont ... honored with the Breakthrough Solution of the Year Award from Platts Global Energy ... ester (FDME). The award was announced at the 18th Platts Global Energy Awards, ...
(Date:12/9/2016)... TORONTO , Dec. 9, 2016 /PRNewswire/ - Portage ... Securities Exchange: PBT.U), is pleased to announce that Biohaven ... New Haven, Connecticut (PRWEB) Dec ... "Company" or "Biohaven") announced today that the U.S. Food ... drug designation request covering its drug candidate BHV-0223, an ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse┬« IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
Breaking Biology Technology: